Cell Death Pathways: Apoptosis, Autophagy and Necrosis

描述（由申请人提供）：本申请申请支持由Guido Kroemer， Junying Yuan和Eileen P. White组织的题为“细胞死亡途径：凋亡，自噬和坏死”的Keystone专题会议，该会议将于2010年3月12日至17日在加拿大不列颠哥伦比亚省温哥华举行。稳态和病理性细胞死亡可通过多种不同的机制发生，包括凋亡、自噬、坏死等。不同细胞死亡方式的形态学和功能定义正在出现，不同致死途径之间的关系正在确定。然而，决定哪些子程序细胞分解的分子开关的确切性质是难以捉摸的。此外，不同细胞死亡方式对避免癌症或退行性疾病的相对贡献仍有待确定。特别是在癌症中，细胞死亡缺陷普遍存在，不死细胞的存活使进展和治疗耐药性成为可能，恢复细胞死亡途径是一个重要的、可实现的治疗目标。最后，不同的细胞死亡模式可能通过仍然难以捉摸的机制保持免疫沉默或触发免疫反应。2010年“细胞死亡途径：凋亡、自噬和坏死”专题讨论会将讨论不同细胞死亡方式的正常调节和致病性功能障碍，提出治疗癌细胞诱导的新策略，并讨论不同细胞死亡类型的免疫原性。同时举行的代谢和癌症进展会议将大大增加跨学科互动的机会，该会议将与本次会议分享主题演讲和两次全体会议。

DESCRIPTION (provided by applicant): This proposal is to request support for a Keystone Symposia meeting entitled Cell Death Pathways: Apoptosis, Autophagy and Necrosis, organized by Guido Kroemer, Junying Yuan and Eileen P. White, which will be held in Vancouver, British Columbia, Canada from March 12 - 17, 2010. Homeostatic and pathological cell death can occur through a multiplicity of different mechanisms including apoptosis, autophagy, necrosis and others. The morphological and functional definitions of distinct cell death modalities are emerging, and the relationships between different lethal pathways are being determined. However, the exact nature of the molecular switches that determine which subroutines cells disintegrate are elusive. Moreover, the relative contributions of different cell death modalities to the avoidance of cancer or degenerative diseases remain to be defined. In cancer, in particular, where defects in cell death are prevalent and the survival of undead cells enables progression and treatment resistance, restoration of cell death pathways is an important and achievable therapeutic goal. Finally, distinct cell death modalities may remain immunologically silent or trigger an immune response, through mechanisms that are still elusive. The 2010 Keystone Symposia meeting on Cell Death Pathways: Apoptosis, Autophagy and Necrosis will address the normal regulation and pathogenic dysfunction of distinct cell death modalities, present new strategies for therapeutic cancer cell induction and address the immunogenicity of distinct cell death types. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Metabolism and Cancer Progression, which will share a keynote address and two plenary sessions with this meeting .